Nab-Paclitaxel

Two treatment regimens showed efficacy as second-line therapy for older adults with non-small cell lung cancer, according to results of separate studies published in Cancer.

The FDA approved atezolizumab plus nab-paclitaxel and carboplatin for the initial treatment of patients with metastatic nonsquamous non-small cell lung cancer, according to a manufacturer-issued press release.